HBT

HBT, officially known as HBT Biyoteknoloji Arge A.Ş, is a promising entrant in the life sciences sector, with a particular focus on advancing the field of biotechnology. Established in 2022 and headquartered in Turkey, the company has set its sights on reshaping how diagnostic kits are developed and used, particularly in the realm of infectious diseases.

Their flagship initiative involves the development of an innovative diagnostic kit for hepatitis B, utilizing a novel biomolecular marker and ensuring compatibility with digital PCR technologies. This ambitious project positions HBT within the intersection of Biotechnology, Healthtech, and Digital Health, areas ripe with transformative potential.

While the company has not yet disclosed any rounds of investment or associated investors, its strategic focus on sustainability and innovation in healthcare diagnostics signals a strong opportunity for venture capitalists seeking to invest in foundational health solutions with long-term global impact.